Merz Therapeutics, Raleigh, NC 27615, USA.
Aetion, New York, NY 10001, USA.
Toxins (Basel). 2024 Aug 16;16(8):362. doi: 10.3390/toxins16080362.
Movement disorders such as cervical dystonia, blepharospasm, and hemifacial spasm negatively impact the quality of life of people living with these conditions. Botulinum toxin (BoNT) injections are commonly used to treat these disorders. We sought to describe patient characteristics, BoNT utilization, and potential adverse events (AEs) among patients with cervical dystonia, blepharospasm, and hemifacial spasm using Optum's de-identified Clinformatics Data Mart Database. Patients were required to have a diagnosis of the specific condition plus evidence of treatment with BoNT between 8/1/2010 and 5/31/2022. Cervical dystonia patients were commonly females (76%) and aged 45 and older (78%); both blepharospasm and hemifacial spasm patients were commonly females (both 69%) and aged 65 and older (61% and 56%, respectively). Anticholinergics were commonly used (65-82% across cohorts), as were peripheral muscle relaxants for cervical dystonia patients specifically (31%). The median number of injections per year was 2 with the median weeks between injections being between 13 and 15. Of the AEs evaluated, dyspnea was identified frequently across all the cohorts (14-20%). The findings were similar for different BoNT formulations. More research is needed to thoroughly describe BoNT utilization, such as the doses injected, and to optimize treatment for patients with these conditions.
运动障碍，如颈肌张力障碍、眼睑痉挛和半面痉挛，会降低患者的生活质量。肉毒毒素（BoNT）注射常用于治疗这些疾病。我们利用 Optum 的去识别 Clinformatics Data Mart 数据库，描述了颈肌张力障碍、眼睑痉挛和半面痉挛患者的患者特征、BoNT 使用情况和潜在不良事件（AEs）。患者需要在 2010 年 8 月 1 日至 2022 年 5 月 31 日期间被确诊为特定疾病，并接受 BoNT 治疗。颈肌张力障碍患者中女性居多（76%），年龄在 45 岁及以上（78%）；眼睑痉挛和半面痉挛患者中女性也居多（均为 69%），年龄在 65 岁及以上（分别为 61%和 56%）。抗胆碱能药物（65-82%）、外周肌肉松弛剂（仅用于颈肌张力障碍患者，31%）的使用较为普遍。每年的注射中位数为 2 次，两次注射之间的中位数间隔为 13-15 周。在所评估的不良事件中，呼吸困难在所有队列中都经常出现（14-20%）。不同 BoNT 制剂的结果相似。需要更多的研究来详细描述 BoNT 的使用情况，如注射剂量，并优化这些疾病患者的治疗方案。
